TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10563682

Group type: EXPERIMENTAL
Intervention: Adolescents with disfiguring burn scars
Number of subjects: 14
Study: 8588407

Group type: EXPERIMENTAL
Intervention: Bronchoscopically controlled suctioning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blind suctioning
Number of subjects: 40
Study: 1961024

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Number of subjects: 5
Study: 7324992

Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (20 mg every 2-3 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 126
Study: 30826253

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 57
Study: 28931394

Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 0
Study: 25460384

Group type: EXPERIMENTAL
Intervention: High inhibition demands through prolonged and intensive practice of the Simon or Eriksen Flanker task
Number of subjects: 0
Study: 23957307

Group type: EXPERIMENTAL
Intervention: Angry face (singleton)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Happy face (singleton)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral faces
Number of subjects: 0
Study: 22294641

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 4.5 g/night
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g/night
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study: 18946484

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg day(-1)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg day(-1)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 195

Group type: COMPARATOR
Intervention: Rilmenidine 1 mg day(-1)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Atenolol 50 mg day(-1)
Number of subjects: 195
Study: 17467226

Group type: EXPERIMENTAL
Intervention: Medical compression stockings (23 to 32 mm Hg) worn daily for 3 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No compression stockings (control group)
Number of subjects: 100
Study: 15711683

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 32
Study: 11784251

Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 9855323

Group type: EXPERIMENTAL
Intervention: Filgrastim administration after chemotherapy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Chemotherapy started within 72 hours of filgrastim therapy
Number of subjects: 2
Study: 7907729

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (500 mg/m2, three times a day for 1 month) followed by oral acyclovir (800 mg four times a day for 6 months)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir followed by oral placebo
Number of subjects: 310

Group type: COMPARATOR
Intervention: Low-dose oral acyclovir (200 or 400 mg, four times a day) followed by placebo
Number of subjects: 310
Study: 2534054

Group type: EXPERIMENTAL
Intervention: Ipratropium (80 micrograms applied intranasally four times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 20
Study: 7352836

Group type: EXPERIMENTAL
Intervention: Long-acting injectable fluphenazine decanoate
Number of subjects: 290

Group type: COMPARATOR
Intervention: Short-acting oral fluphenazine hydrochloride
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 290

Group type: COMPARATOR
Intervention: Fluphenazine hydrochloride
Number of subjects: 290
Study: 30113196

Group type: EXPERIMENTAL
Intervention: Current conjecture group
Number of subjects: 432

Group type: COMPARATOR
Intervention: Reproduced conjecture group
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Controlled lab experiment
Number of subjects: 432
Study: 28394819

Group type: EXPERIMENTAL
Intervention: Quiet atmosphere during SCT assessment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noisy atmosphere during SCT assessment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quiet atmosphere for year 1 and 2 residents
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noisy atmosphere for year 1 and 2 residents
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quiet atmosphere for year 3 and 4 residents
Number of subjects: 42

Group type: COMPARATOR
Intervention: Noisy atmosphere for year 3 and 4 residents
Number of subjects: 42
Study: 25998279

Group type: EXPERIMENTAL
Intervention: Citicoline
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 23595943

Group type: EXPERIMENTAL
Intervention: NCC-AT
Number of subjects: 18
Study: 21242842

Group type: EXPERIMENTAL
Intervention: Postoperative fever
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: LMD with postoperative fever
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: ACDF with postoperative fever
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: LDF with postoperative fever
Number of subjects: 578
Study: 19741381

Group type: EXPERIMENTAL
Intervention: Use of structured checklist for ICU handoffs
Number of subjects: 332

Group type: COMPARATOR
Intervention: No checklist used
Number of subjects: 332
Study: 18035002

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ferguson haemorrhoidectomy
Number of subjects: 100
Study: 17249431

Group type: EXPERIMENTAL
Intervention: CollaCote
Number of subjects: 25

Group type: COMPARATOR
Intervention: No barrier
Number of subjects: 25
Study: 12728088

Group type: COMPARATOR
Intervention: Thyroxine (T4) alone (group 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) plus Triiodothyronine (T3) (group 2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (matched infants)
Number of subjects: 14
Study: 10335757

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 8937947

Group type: EXPERIMENTAL
Intervention: Collaborative quality improvement program
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Educational programs on CHF, feedback of Phase I data, clinical care pathway design, improvement of emergency department management, patient education and discharge planning
Number of subjects: 1402
Study: 2020613

Group type: EXPERIMENTAL
Intervention: Bromfenac 5 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Bromfenac 25 mg and Ibuprofen 400 mg
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study: 6982803

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) tablets, 0.5 mg, four times daily for five days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31693429

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and rituximab (pola‐BR)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bendamustine and rituximab (BR)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and obinutuzumab (pola‐BG)
Number of subjects: 107
Study: 28727183

Group type: EXPERIMENTAL
Intervention: Nurse-led smartphone-based self-management programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Existing nurse-led diabetes service
Number of subjects: 128
Study: 26489809

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily (doubled after 12 weeks)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Amiloride plus Hydrochlorothiazide (5 mg + 12.5 mg daily, doubled after 12 weeks)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg daily (doubled after 12 weeks)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Amiloride plus Hydrochlorothiazide
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 441

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 441
Study: 25016507

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.5% (0.5 mL/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: ropivacaine 0.2% (0.5 mL/kg)
Number of subjects: 56
Study: 22653094

Group type: EXPERIMENTAL
Intervention: Eperisone with tramadol (100 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tizanidine with tramadol (100 mg/day)
Number of subjects: 60
Study: 20367520

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 18533562

Group type: EXPERIMENTAL
Intervention: Video laryngoscope under midazolam-induced sleep
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional physical examination and video laryngoscope when awake
Number of subjects: 132
Study: 16053212

Group type: EXPERIMENTAL
Intervention: PETN-100
Number of subjects: 25

Group type: COMPARATOR
Intervention: PETN-50
Number of subjects: 25
Study: 11954883

Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 5 l of physiological fluid
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 10 l of physiological fluid
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intra-articular lavage with 0.5-1.5 l of physiological fluid
Number of subjects: 98
Study: 10512405

Group type: EXPERIMENTAL
Intervention: Rifampin, 10 mg/kg per day in two divided doses for 18+/‐20 months
Number of subjects: 24
Study: 8554930

Group type: EXPERIMENTAL
Intervention: L-NMMA infusion (0.1, 0.2, 0.5, 1.0 and 2.0 mg kg‐1 h‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 8
Study: 2028917

Group type: EXPERIMENTAL
Intervention: ICE (ice and water cooling system)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: FREON (Freon-based cooling system)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CRS (Coast Guard chemical response suit)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CONTROL (self‐contained breathing apparatus with shorts, shirt, helmet, and shoes)
Number of subjects: 9
Study: 7005939

Group type: EXPERIMENTAL
Intervention: Mammographic screening procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study: 31121302

Group type: EXPERIMENTAL
Intervention: Predefined center and surgeon credentials established to manage learning effects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stratified randomization by site
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Stratified randomization by surgeon
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subsequent adjustment in analysis for learning and clustering effects
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Funder led changes in response to referees
Number of subjects: 50
Study: 28057077

Group type: EXPERIMENTAL
Intervention: Ice ingestion with a long rest interval (20 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ice ingestion with a short rest interval (5 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cold water ingestion (4 °C)
Number of subjects: 7
Study: 27180353

Group type: EXPERIMENTAL
Intervention: 1-step self-etch adhesive (1-SEA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 3-step etch-and-rinse adhesive (3-E&RA)
Number of subjects: 200
Study: 22960432

Group type: EXPERIMENTAL
Intervention: Prompting form
Number of subjects: 60
Study: 20542976

Group type: EXPERIMENTAL
Intervention: 3-month multidisciplinary intervention (n=33)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care group (n=32)
Number of subjects: 75
Study: 19470318

Group type: EXPERIMENTAL
Intervention: Anti-pseudomonal treatment (cycled therapy) including inhaled tobramycin (300 mg BID for 28 days) and oral ciprofloxacin (15-20 mg/kg BID for 14 days)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Culture-based therapy based on recovery of Pseudomonas aeruginosa from quarterly respiratory cultures
Number of subjects: 306
Study: 17223346

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES) of gastrocnemius and soleus at three different timings during normal gait
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unstimulated trials
Number of subjects: 5
Study: 12937809

Group type: EXPERIMENTAL
Intervention: Butea superba
Number of subjects: 0
Study: 11100891

Group type: EXPERIMENTAL
Intervention: Frisby test for stereopsis assessment
Number of subjects: 0
Study: 8737105

Group type: EXPERIMENTAL
Intervention: Metoprolol 50-100 mg b.i.d. (n = 106)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Xamoterol 100-200 mg b.i.d. (n = 104)
Number of subjects: 210
Study: 1534312

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Nifedipine retard
Number of subjects: 540
Study: 6397848

Group type: EXPERIMENTAL
Intervention: De-Nol tablets (four times daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cimetidine tablets (400 mg, twice daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: De-Nol tablets
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cimetidine tablets
Number of subjects: 50
Study: 30664828

Group type: EXPERIMENTAL
Intervention: 15 keto fluprostenol isopropyl ester gel (80 µgr/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 40
Study: 25331010

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 120
Study: 26034917

Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study: 23704972

Group type: EXPERIMENTAL
Intervention: Painless examination (general clinical exam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Painful examination (pocketing and bleeding on probing exam)
Number of subjects: 0
Study: 21303639

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) patients (older than 70 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM) patients (younger than 70 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes mellitus (T1DM) patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 19577798

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice daily
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 17570951

Group type: EXPERIMENTAL
Intervention: Olanzapine (14.0 +/- 5.0 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Perazine (360.0 +/- 196.0 mg/day) + Carbamazepine (404.0 +/- 229.0 mg/day)
Number of subjects: 23
Study: 15549464

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (5 times)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (10 times)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (normal saline 1 ml)
Number of subjects: 168
Study: 11298666

Group type: EXPERIMENTAL
Intervention: Cyclandelate (1600 mg)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 9813517

Group type: EXPERIMENTAL
Intervention: Low-flow ventilation (1 litre min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-flow ventilation (6 litre min‐1)
Number of subjects: 20
Study: 7544074

Group type: EXPERIMENTAL
Intervention: Aprotinin (6 million KIU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2746403

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Mock adjustment (placebo)
Number of subjects: 62
Study: 332090

Group type: EXPERIMENTAL
Intervention: Mycophenolic acid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31812463

Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine with 30 μg LTh(αK) adjuvant (group 1)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Intranasal influenza vaccine with 45 μg LTh(αK) adjuvant (group 2)
Number of subjects: 354

Group type: COMPARATOR
Intervention: Intranasal influenza vaccine with 22.5 μg HA antigen alone (control group 3)
Number of subjects: 354
Study: 31225667

Group type: EXPERIMENTAL
Intervention: TAVIE en m@rche
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (hyperlinks to public websites)
Number of subjects: 39
Study: 28151883

Group type: EXPERIMENTAL
Intervention: Glucocorticoid users
Number of subjects: 8704

Group type: COMPARATOR
Intervention: Non-glucocorticoid users (controls)
Number of subjects: 8704
Study: 25985907

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus atorvastatin 10 mg
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: No change in therapy
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Double atorvastatin dose
Number of subjects: 1534

Group type: EXPERIMENTAL
Intervention: Physicians' treatment recommendations
Number of subjects: 1534
Study: 23729226

Group type: EXPERIMENTAL
Intervention: Netupitant with midazolam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Netupitant with erythromycin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Netupitant with dexamethasone (300 mg)
Number of subjects: 45
Study: 21378081

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 19951408

Group type: EXPERIMENTAL
Intervention: 0.1 mg daily of chicken type II collagen (CCII)
Number of subjects: 503

Group type: COMPARATOR
Intervention: 10 mg once a week of methotrexate (MTX)
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CCII
Number of subjects: 503

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CCII and MTX
Number of subjects: 503
Study: 16983146

Group type: EXPERIMENTAL
Intervention: Plasma phospholipid (PL) DHA levels above the median
Number of subjects: 228

Group type: COMPARATOR
Intervention: Plasma phospholipid (PL) DHA levels below the median
Number of subjects: 228
Study: 12846051

Group type: EXPERIMENTAL
Intervention: 7.5‐15 mg of prednisolone (PRE) daily for one to three months followed by methotrexate (MTX) 5‐15 mg weekly if needed
Number of subjects: 245

Group type: COMPARATOR
Intervention: sulfasalazine (SAL), supplemented with lowest possible corticosteroid dose if needed
Number of subjects: 245
Study: 10496191

Group type: EXPERIMENTAL
Intervention: 6-month supervised and graded exercise program
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 33
Study: 8601981

Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (200 mg in 50 ml normal saline solution intravenously)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (50 ml normal saline solution intravenously)
Number of subjects: 24
Study: 1761642

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG), 400 mg/kg daily for 3 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 7346177

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment, given b.i.d. (twice daily)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) treatment, with dose reduction
Number of subjects: 8
Study: 3002672

Group type: EXPERIMENTAL
Intervention: Enalapril (10 to 40 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (80 to 240 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril with hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol with hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiazide-induced conditions
Number of subjects: 0
Study: 29925890

Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI) coupled to functional electrical stimulation (FES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham functional electrical stimulation (FES)
Number of subjects: 0
Study: 26482590

Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiofrequency-targeted Vertebral Augmentation (RF-TVA)
Number of subjects: 80
Study: 24486366

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthcare provider recommendation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital-based practices as primary source of prenatal care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived interpersonal support for influenza immunization
Number of subjects: 0
Study: 23012836

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1 mg x kg(‐1) intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 60
Study: 20047897

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 microg kg(‐1) in 2 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physostigmine (30 microg kg(‐1) in 15 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and alfentanil (same doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of physostigmine and alfentanil
Number of subjects: 20
Study: 18806506

Group type: EXPERIMENTAL
Intervention: Mechanical arm trainer
Number of subjects: 54

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Both groups (Mechanical arm trainer and Electrical stimulation)
Number of subjects: 54